Prognostic Indicators for Radiation-induced Breast Fibrosis

NCT05031065 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 4

Last updated 2025-06-27

No results posted yet for this study

Summary

To study the inflammatory response during and after radiotherapy, especially by measuring the concentration of an enzyme called autotaxin and its product LPA in the blood plasma.

Conditions

Interventions

RADIATION

Breast Cancer Radiotherapy

4000-4250 cGy in 15-16 daily fractions

Sponsors & Collaborators

  • AHS Cancer Control Alberta

    lead OTHER

Principal Investigators

  • Zsolt Gabos, MD · AHS-CCI

Eligibility

Min Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-24
Primary Completion
2025-05-05
Completion
2025-05-05

Countries

  • Canada

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05031065 on ClinicalTrials.gov